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Background and aims: Metalloproteinases (MMPs) are considered to be key enzymes in the 
pathogenesis of abdominal aortic aneurysms (AAA), with elevated levels in diseased aorta and 
in patient sera. Statins seem to exert an inhibitory effect on MMP activity in the aortic wall. 
No data exist on the effect of statins on serum activity of MMPs and inﬂ  ammatory cytokines 
(interleukins, IL).
Methods: The serum activities of MMP2 and MMP9, osteoprotegerin (OPG), and IL6 and 
IL10 in 63 patients undergoing elective infrarenal aneurysm repair were measured on the day 
before surgery. Levels were correlated to statin therapy and aneurysm diameter.
Results: There was no signiﬁ  cant difference between the two groups in the activity of circulating 
levels of MMP2/9, OPG, and IL6/10 in patients with infrarenal aortic aneurysm. IL6 levels in 
patients with AAA larger than 6 cm were signiﬁ  cantly elevated; differences in serum activities 
of MMP2/9, OPG, and IL10 were not related to AAA diameter.
Conclusion: Serum activities of MMP2/9, OPG, and IL6/10 are not correlated to statin therapy; 
IL6 levels are higher in patients with large aneurysms. Hence the effect of statin therapy in the 
treatment of aneurismal disease remains to be elucidated.
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Introduction
Metalloproteinases (MMPs) are believed to play a key role in the development of 
aneurismal disease of the aorta, although the precise mechanisms leading to aneurysm 
formation remain unclear. Elevated levels of MMP2 and MMP9 have been shown in the 
extract tissue from surgical specimens and in the sera of patients with aortic aneurysm, 
compared with nondiseased aorta and healthy controls, respectively (Tamarina at al 
1997; Hovsepian et al 2000; Lindholt et al 2000; Annabi et al 2002).
A common feature of vascular disease and aneurysm formation is an inﬂ  amma-
tory process in the aneurismal wall with invasion of monocytes and macrophages 
and increased levels of interleukins (IL) such as IL6 (Dawson et al 2007). Hence one 
therapeutic approach in the conservative management of patients with aortic aneurysm 
aims to inhibit this inﬂ  ammation and matrix turnover by statins and angiotensin II 
inhibitors (Abisi et al 2007; Evans et al 2007). Simvastatin has been shown to suppress 
experimental aneurysm formation in rats (Kalyanasundaram et al 2006). Currently, 
the cessation of smoking, and antiplatelet and statin therapy are recommended in 
conservative treatment of patients with small aortic aneurysms (Diehm et al 2007; 
Golledge et al 2007). Statin treatment has been shown to reduce circulating levels of 
MMPs in patients with acute coronary syndrome (Tziakas et al 2004). However, no 
data are available on the effect of statins on circulating levels of representative MMPs 
and cytokines in patients with abdominal aortic aneurysm (AAA). Hence we studied Vascular Health and Risk Management 2008:4(6) 1434
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the serum activity of MMP2/9, osteoprotegerin (OPG) – a 
recently identiﬁ  ed promoter of vascular disease that has been 
correlated to aneurysm expansion (Moran et al 2005) – and 
IL6 and IL10 in patients undergoing elective infrarenal aortic 
aneurysm repair and correlated the measurements to statin 
therapy and aneurysm diameter.
Methods
The study was approved by the local ethics committee 
and informed consent was obtained from all patients 
preoperatively. Sixty-three patients undergoing elective 
infarenal aneurysm repair were recruited for this study; 
25 patients were on regular statin therapy before surgery. 
Statin therapy lasted for at least 4 weeks before surgery; 
23 patients were on simvastatin at a dose of 10–40 mg once 
daily, and 2 patients were on ﬂ  uvastatin 80 mg once daily. 
All subjects had their surgical procedure at the Department 
of Thoracic and Vascular Surgery, University of Ulm, 
between 2005 and 2007. Blood samples were taken 1 day 
before surgery, immediately centrifuged for 10 min at 
4000 rpm, and stored at –80 °C until measurements.
Matrix metalloproteinase activity 
bioimmunoassay
Active forms of MMP2 and MMP9 were measured using 
speciﬁ  c quantitative activity bioimmunoassays (Chemicon) 
according to the manufacturer´s instructions. MMP2 
and MMP9 activity was expressed in nanograms per 
milliliter.
Osteoprotegerin
OPG activity was measured using a commercially available 
Enzyme Linked Immuno Sorbent Assay (BioCat) according 
to the manufacturer´s instructions. OPG activity was 
expressed in picograms per milliliter.
Interleukin 6 and 10
Levels of IL6 and IL10 were determined using a Enzyme 
Linked Immuno Sorbent Assay (R&D Systems). The 
manufacturer’s instructions were followed throughout.
Statistical analysis
For discrete variables, absolute and relative frequencies are 
given. For continuous frequencies, median values and range 
are applied as they were not normally distributed. To calculate 
the signiﬁ  cance of difference in activity between the treat-
ment groups the Mann Whitney U test was used. To calculate 
the signiﬁ  cance of the relationship between AAA diameter 
and serum activity the Kruskal-Wallis one way analysis 
of variance on ranks was applied. P values 0.05 were 
regarded as signiﬁ  cant. Statistical analysis was performed 
in collaboration with the Department of Biometry using the 
computer program SigmaStat.
Results
Patient data
The two patient groups were comparable for age, aneurysm 
diameter, sex, and pre-existing risk factors (Table 1).
Biomarker activity as a function of statin 
therapy
There was no statistically significant difference in the 
serum activity of MMP2/9, OPG, and IL6/10 in patients 
with or without statin therapy: median values for MMP2 
activity were 209 vs 211 ng/mL respectively, and for MMP9 
activity 38 vs 37 ng/mL, respectively. OPG values were 
417 vs 430 pg/mL, respectively. IL6 and IL10 levels also 
did not differ signiﬁ  cantly: 5 vs 7 pg/mL and 6 vs 5 pg/mL, 
respectively (Figures 1–5).
Biomarker activity as a function of AAA 
diameter
To test the correlation of biomarker activity and AAA diam-
eter, patients were divided into 3 groups: AAA diameter 5 
cm, 5.1–6.0 cm, 6.0 cm. Using this separation there was no 
difference in the serum activity of MMP2, MMP9, OPG, and 
IL10; aneurysms 6 cm in diameter showed signiﬁ  cantly 
higher levels of IL6 than smaller aneurysms (Table 2).
Table 1 Demographic data of 63 patients undergoing elective 
aneurysm repair according to statin use
Statin
n = 25
No statin
n = 38
p value
Mean age (years) 67 (52–80) 74 (55–88) 0.064a
AAA diameter (cm) 6 (4–9) 6 (5–9) 0.065a
No. of men 25 (100%) 34 (89%) 0.145b
Smokers 11 (44%) 18 (47%) 0.803b
Hypertension 23 (92%) 28 (74%) 0.103b
Ischemic heart disease 13 (52%) 14 (37%) 0.301b
Diabetes mellitus 4 (16%) 5 (13%) 0.732b
Notes: Values of age and AAA diameter are given as median and range; other values 
are expressed as absolute numbers and percentages. aMann-Whitney U – test; 
bFisher’s exact test.
Abbreviation: AAA, abdominal aortic aneurysm.Vascular Health and Risk Management 2008:4(6) 1435
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Discussion
This in vivo study examined the association between 
statin treatment and the serum activity of potent matrix 
remodeling proteases and inﬂ  ammatory cytokines known 
to be present in patients suffering from aortic aneurysm. In 
recent years increasing understanding of the pathogenesis 
of AAA has generated hope that pharmacotherapy can be 
applied to patients with small aortic aneurysms (Diehm 
et al 2007). In vitro and in vivo data have been published 
that show that HMG CoA reductase inhibitors (statins) may 
limit AAA growth by inhibitory action on MMP activity 
in the aortic wall (Schouten et al 2006; Evans et al 2007). 
Hence statin therapy is now recommended in the conserva-
tive management of patients with aortic aneurysms to slow 
aneurysm growth rate (Golledge et al 2006). Circulating 
levels of MMPs and OPG are elevated in aneurysm 
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Figure 1 Serum activity of MMP9 according to statin use; median values were 38 and 
37 ng/mL, respectively (p = 0.868).
Abbreviation: MMP, metalloproteinase.
Figure 2 Serum activity of MMP2 according to statin use; median values were 209 and 
211 ng/mL, respectively (p = 0.394).
Abbreviation: MMP, metalloproteinase.
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Figure 3 Serum levels of IL10 according to statin use; median values were 6 and 
5 pg/mL, respectively (p = 0.679).
Abbreviation: IL, interleukin.
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Figure 4 Serum levels of IL6 according to statin use; median values were 5 and 
7 pg/mL, respectively (p = 0.085).
Abbreviation: IL, interleukin.
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Figure 5 Serum activity of OPG according to statin use; median values did not differ 
signiﬁ  cantly: 417 vs 430 pg/mL, respectively (p = 0.369).
Abbreviation: OPG, osteoprotegerin.Vascular Health and Risk Management 2008:4(6) 1436
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patients, and monitoring of these markers may be helpful in 
managing these patients and surveying medical treatment. 
In patients with unstable angina, statin administration reduces 
circulating levels of inﬂ  ammatory markers (Tousoulis et al 
2006). In patients with aortic aneurysms no data are available 
on circulating levels of MMPs and other inﬂ  ammatory 
cytokines in relation to statin therapy. Hence we analyzed 
blood samples from patients undergoing elective infrarenal 
aortic aneurysm repair for the levels of MMP2 and MMP9, 
OPG, and IL6 and 10 and correlated the data to statin therapy 
and aneurysm diameter. Surprisingly, statin therapy was 
not correlated to the circulating levels of the investigated 
biomarkers. Serum levels in patients on statin therapy were 
similar to those in patients without statin therapy. Correla-
tion to aneurysm diameter did not reveal signiﬁ  cant differ-
ences between small, medium-sized, and large aneurysms: 
patients with small aneurysms, smaller than 5 cm, showed 
similar activity of MMPs, OPG, and IL10 as did patients with 
aneurysms larger than 5 cm; however, patients with aneu-
rysms larger than 6 cm showed signiﬁ  cantly higher levels 
of IL6 than patients with smaller aneurysms. This result is 
in line with those of other investigators who demonstrated 
that the aortic aneurysm was the source of IL6 and who 
correlated IL6 levels to aneurysm surface (Dawson et al 
2007). Nevertheless, our results partly contradict ﬁ  ndings 
that showed that MMP2 levels were correlated to aneu-
rysm expansion and MMP9 levels to aneurysm rupture 
(Petersen et al 2002). Other investigators have reported on 
elevated serum levels of MMP9 in AAA compared with 
healthy controls and patients with aorto-iliac occlusive 
disease (McMillan and Pearce 1999; Hovsepian et al 2000). 
However, in this context several issues are now discussed.
First: studies on human blood samples in patients with 
aortic aneurysm are limited, as patients are usually referred 
for surgical repair; therefore our measurements are only 
snapshots in the course of aneurismal expansion and no 
data on growth rates were available. So the relationship 
between statin treatment and aneurysm expansion could not 
be determined – a problem that has already been conﬁ  rmed 
by other investigators (Abisi et al 2008). Subsequently the 
lack of correlation between statin therapy and biomarker 
activity may not necessarily document a lack of effect of 
statins on aneurysm growth.
Second: Results are contradictory on the relationship 
between circulating levels of MMPs and degenerative 
mechanisms in the wall of aortic aneurysms. On the one 
hand it has been shown that circulating MMP9 levels fell 
significantly after aneurysm exclusion (Watanabe et al 
2006); on the other hand the negative predictive value of 
normal MMP9 levels is about 52% (Hovsepian et al 2000). 
It appears that proteinases from the tissue compartment – the 
aortic wall – are not released to the plasmatic compartment 
and therefore MMP levels in the serum of patients do not 
reﬂ  ect the situation in the aneurismal wall. Hence further 
investigations should focus on the correlation between tissue 
activitiy and serum activitiy in patients with AAA.
Third: Most studies on the role of MMPs and other 
inflammatory markers in aortic aneurysms use healthy 
volunteers or patients with arterial occlusive disease as 
control. Only a few investigations have compared patients 
with aortic aneurysm and statin therapy (Evans et al 2007; 
Abisi et al 2008).
Finally, the power of our investigation was limited (20%) 
and the lack of signiﬁ  cant correlations may be related to the 
relatively small number of patients. However, our results, 
together with published research, suggest that statins may exert 
an inhibitory effect on proteolytic activity in the aneurismal 
wall which is not reﬂ  ected in the serum of aneurysm patients; 
hence it remains questionable if MMPs and other inﬂ  amma-
tory markers such as ILs and OPG can serve as biomarkers 
in aneurismal disease. In addition the precise mechanisms of 
statin therapy in the conservative treatment of aortic aneurysm 
have yet to be examined. To elucidate the role of statins on 
aneurysm growth long-term follow up in clinical trials would 
Table 2 Correlation of biomarker activity and aneurysm diameter
AAA diameter 5 cm (n = 11) 5.1–6 cm (n = 32) 6 cm (n = 20) P value
MMP2 (ng/mL) 212 (155–347) 209 (122–412) 181 (122–351) 0.726a
MMP9 (ng/mL) 37 (29–465) 38 (25–216) 40 (24–100) 0.850a
OPG (pg/mL) 523 (229–5861) 410 (214–921) 413 (217–907) 0.701a
IL10 (pg/mL) 6.4 (–1.06–19.82) 4 (1–17) 5 (–3–21) 0.465a
IL6 (pg/mL) 3.67 (2.72–42.26) 4 (3–46) 10 (5–20)b 0.009a
Notes: Values are given as median and range. aKruskal-Wallis one way analysis of variance on ranks; bsigniﬁ  cant compared with small (5 cm) and medium-sized (5.1–6 cm) 
aneurysms
Abbreviations: AAA, abdominal aortic aneurysm; IL, interleukin; MMP, metalloproteinase; OPG, osteoprotegerin.Vascular Health and Risk Management 2008:4(6) 1437
Biomarker activity in AAA patients according to statin use
be necessary. However, statins have been documented to be 
associated with reduced cerebro-cardio-vascular mortality in 
vascular patients and patients undergoing AAA surgery (Kertai 
et al 2004; Welten et al 2007). Consequently most vascular 
patients are on statin treatment and such a clinical trial would 
prove ethically impossible. Nevertheless, further investigations 
on the mechanisms of aneurysm growth and effects of phar-
macological agents are necessary to develop the best treatment 
regimen for patients with aortic aneurysms.
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